Y-mAbs Financial Results and Recent Corporate Developments

 

• Q4 2022 DANYELZA® record net product revenues of $16.4 million, driving YoY growth of 71% and 31% sequential increase compared to Q3 2022

• DANYELZA conditional marketing authorization granted in China

• Management reiterates 2023 financial guidance

• First ever SADA Phase I trial opened

• Cash and cash equivalents of $105.8 million as of December 31, 2022, anticipated runway into the first quarter 2026

• The Company will host a conference call on Friday, March 31, 2023, at 9 a.m. EST

Y-mAbs will host a conference call on Friday, March 31, 2023, at 9 a.m. Eastern Time. To participate in the call, please use the following dial-in information.

Investors (domestic):	877-407-0792
Investors (international):	201-689-8263
Conference ID:	13736579

To access a live webcast of the update, please use this link.

https://finance.yahoo.com/news/y-mabs-reports-fourth-quarter-200100169.html